Host-Directed Therapies for Tackling Multi-Drug Resistant Tuberculosis: Learning From the Pasteur-Bechamp Debates (Q41085601)

26 September 2017

Host-Directed Therapies for Tackling Multi-Drug Resistant Tuberculosis: Learning From the Pasteur-Bechamp Debates (English)

1 reference

26 September 2017

multiple drug resistance

1 reference

1 reference

Markus Maeurer

2

0 references

Alimuddin Zumla

object named as

Alimuddin Zumla

series ordinal

1

0 references

Mahdad Noursadeghi

0 references

author name string

Host-Directed Therapies Network (HDT-NET) Consortium

series ordinal

3

1 reference

PubMed ID

26219693

26 September 2017

language of work or name

English

0 references

publication date

28 July 2015

1 reference

Clinical Infectious Diseases

26 September 2017

1 reference

26 September 2017

61

1 reference

26 September 2017

9

1 reference

26 September 2017

1432-1438

1 reference

Ensuring rational introduction and responsible use of new TB tools: outcome of an ERS multisector consultation

26 September 2017

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV631

Multidrug-resistant tuberculosis--can the tide be turned?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV631

Reflections on the white plague

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV631

World TB Day 2014: finding the missing 3 million

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV631

Tuberculosis diagnostics and biomarkers: needs, challenges, recent advances, and opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV631

Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resista

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV631

New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV631

Progress in tuberculosis vaccine development and host-directed therapies--a state of the art review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV631

Trend in case detection rate for all tuberculosis cases notified in Ebonyi, Southeastern Nigeria during 1999-2009.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV631

Burden of tuberculosis at post mortem in inpatients at a tertiary referral centre in sub-Saharan Africa: a prospective descriptive autopsy study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV631

Tuberculosis and tuberculosis/HIV/AIDS-associated mortality in Africa: the urgent need to expand and invest in routine and research autopsies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV631

Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV631

Drug resistance beyond extensively drug-resistant tuberculosis: individual patient data meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV631

Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV631

A four-month gatifloxacin-containing regimen for treating tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV631

High-dose rifapentine with moxifloxacin for pulmonary tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV631

Tuberculosis treatment and management--an update on treatment regimens, trials, new drugs, and adjunct therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV631

Viewpoint: Scientific dogmas, paradoxes and mysteries of latent Mycobacterium tuberculosis infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV631

The global emergency of tuberculosis: what is the cause?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV631

The history of tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV631

Adjunct immunotherapies for tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV631

Cellular therapy in tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV631

Autophagy in the fight against tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV631

Advancing host-directed therapy for tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV631

Ethics of healthcare research in developing countries.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV631

Moving to research partnerships in developing countries

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV631

Partnering with local scientists should be mandatory.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV631

RePORT International: Advancing Tuberculosis Biomarker Research Through Global Collaboration

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV631

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV631

Tackling the tuberculosis epidemic in sub-Saharan Africa--unique opportunities arising from the second European Developing Countries Clinical Trials Partnership (EDCTP) programme 2015-2024.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV631

Randomized Trial of Type 1 and Type 3 Oral Monovalent Poliovirus Vaccines in Newborns in Africa

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV631

21 January 2018

Identifiers

DOI

10.1093/CID/CIV631

1 reference

26 September 2017

1 reference

PubMed ID

26219693